Utility of 18F-FDG PET/CT in medical care of a promyelocytic sarcoma

Nicolas Jacquet-Francillon; Jerome Cornillon; Pascale Flandrin; Lauren Rigollet; Nathalie Prevot; Emmanuelle Tavernier; Pierre-Benoit Bonnefoy

doi:10.1016/j.retram.2020.103272

Utility of 18F-FDG PET/CT in medical care of a promyelocytic sarcoma

Curr Res Transl Med. 2021 May;69(2):103272. doi: 10.1016/j.retram.2020.103272. Epub 2021 Jan 18.

Authors

Nicolas Jacquet-Francillon¹, Jerome Cornillon², Pascale Flandrin³, Lauren Rigollet⁴, Nathalie Prevot⁵, Emmanuelle Tavernier⁶, Pierre-Benoit Bonnefoy⁷

Affiliations

¹ Department of Nuclear Medicine, University Hospital, Saint-Etienne, France. Electronic address: [email protected].
² Lucien-Neuwirth Institute of Cancerology, Clinical Hematology Department, Saint-Priest-en-Jarez, France. Electronic address: [email protected].
³ Hematology Laboratory, University Hospital, Saint-Etienne, France. Electronic address: [email protected].
⁴ Cytology Laboratory, University Hospital, Saint-Etienne, France. Electronic address: [email protected].
⁵ Department of Nuclear Medicine, University Hospital, Saint-Etienne, France. Electronic address: [email protected].
⁶ Lucien-Neuwirth Institute of Cancerology, Clinical Hematology Department, Saint-Priest-en-Jarez, France. Electronic address: [email protected].
⁷ Department of Nuclear Medicine, University Hospital, Saint-Etienne, France. Electronic address: [email protected].

PMID: 33476934
DOI: 10.1016/j.retram.2020.103272

Abstract

Promyelocytic sarcoma is an uncommon solid tumor made up of myeloblasts. It is characterized, like acute promyelocytic leukemia (APL), by a chromosomal translocation t(15;17) involving the retinoic acid receptor alpha (RARalpha) and the promyelocytic gene (PML). The diagnosis and monitoring of promyelocytic sarcoma is a challenge due to the rarity and severity of the disease. We describe a case with several initial sites and without APL. The patient was monitored with regular 18F-FDG PET/CT from diagnosis to complete response. The evolution of PET/CT imageries was compared to the quantification of PML-RARα fusion gene by RQ-PCR. In promyelocytic sarcoma medical care, 18F-FDG PET/CT appears to be an attractive tool for finding targets for biopsy, for the primary staging, for assessing therapeutic response and for detecting early relapse.

Keywords: 18F-FDG PET/CT; PML-RARalpha; Promyelocytic sarcoma.

MeSH terms

Fluorodeoxyglucose F18
Granulocyte Precursor Cells
Humans
Leukemia, Promyelocytic, Acute* / diagnostic imaging
Leukemia, Promyelocytic, Acute* / genetics
Oncogene Proteins, Fusion / genetics
Positron Emission Tomography Computed Tomography
Sarcoma*

Substances

Oncogene Proteins, Fusion
Fluorodeoxyglucose F18